Skip to main content

Table 3 Adverse events during the study period

From: Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial

 

All patients (n = 13)

Level 2 (n = 7)

All Gr

Gr 3–4

All Gr

Gr 3–4

n

(%)

n

(%)

n

(%)

n

(%)

Neutropenia

1

(7.7)

0

(0)

1

(14.3)

0

(0)

Anemia

10

(76.9)

0

(0)

4

(57.1)

0

(0)

Thrombocytopenia

2

(15.4)

0

(0)

1

(14.3)

0

(0)

Anorexia

5

(38.5)

1

(7.7)

3

(42.9)

0

(0)

Nausea

2

(15.4)

0

(0)

1

(14.3) a

0

(0)

Vomiting

3

(12.1)

0

(0)

2

(28.6) a

0

(0)

Diarrhea

10

(76.9)

2

(15.4)

6

(85.7)

1

(14.3) a

Oral mucositis

5

(38.5)

0

(0)

1

(14.3)

0

(0)

Paronychia

2

(15.4)

0

(0)

1

(14.3)

0

(0)

Skin rash

9

(69.2)

1

(7.7)

4

(57.1)

1

(14.3)

Fatigue

1

(7.7)

1

(7.7)

1

(14.3)

1

(14.3)

Increased ALT

1

(7.7)

0

(0)

1

(14.3)

0

(0)

Increased AST

1

(7.7)

0

(0)

1

(14.3)

0

(0)

Increased creatinine

2

(15.4)

0

(0)

1

(14.3)

0

(0)

Hyponatremia

1

(7.7)

2

(15.4)

1

(14.3)

1

(14.3)

  1. Abbreviations: Gr grade, AST aspartate aminotransferase, ALT alanine aminotransferase
  2. a DLTs in level 2 cohort comprised Grade 2 nausea and vomiting (n = 1), and Grade 3 diarrhea (n = 1)
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us